Clinical/contract research organisations (CROs) in particular are among the strongest growth sectors of the pharmaceutical industry, with many firms across the sector experiencing double- digit annual growth. This growth is driven by the trend for increased outsourcing by pharmaceutical and biotechnology companies looking to shift fixed to variable costs and access specialist capabilities not found in-house, and an overall increase in biopharmaceutical R&D spending. CROs have also become one of the most active sectors for M&A, with larger players consolidating to achieve critical mass, as well as completing bolt-on acquisitions to offer a more comprehensive service offering.
Our team has a strong track-record in successful CRO transactions.
Subscribe to receive our latest sector-specific research on M&A activity and fundraisings:
Find out more View All
We are delighted to announce that Results Healthcare acted as exclusive financial advisor to GHO Capital, on its acquisition, alongside management, of Sterling Pharma Solutions - a specialist in complex and difficult to manufacture active pharmaceutical ingredients (APIs).